Form 8-K - Current report:
SEC Accession No. 0001104659-26-025331
Filing Date
2026-03-09
Accepted
2026-03-09 17:18:10
Documents
14
Period of Report
2026-03-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm268321d1_8k.htm   iXBRL 8-K 35812
2 EXHIBIT 99.1 tm268321d1_ex99-1.htm EX-99.1 14423
6 GRAPHIC tm268321d1_ex99-1img001.jpg GRAPHIC 2094
  Complete submission text file 0001104659-26-025331.txt   223265

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA uthr-20260309.xsd EX-101.SCH 3011
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE uthr-20260309_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE uthr-20260309_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT tm268321d1_8k_htm.xml XML 3102
Mailing Address 1000 SPRING ST SILVER SPRING MD 20910
Business Address 1000 SPRING ST SILVER SPRING MD 20910 3016089292
UNITED THERAPEUTICS Corp (Filer) CIK: 0001082554 (see all company filings)

EIN.: 521984749 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26301 | Film No.: 26736173
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)